Last reviewed · How we verify
TRIGEL
TRIGEL is a medication that works by lowering the levels of triglycerides in the blood.
TRIGEL is a medication that works by lowering the levels of triglycerides in the blood. Used for Hypertriglyceridemia.
At a glance
| Generic name | TRIGEL |
|---|---|
| Also known as | Lecigon |
| Sponsor | LobSor Pharmaceuticals AB |
| Drug class | Fatty acid synthase inhibitor |
| Target | Fatty acid synthase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
It does this by inhibiting the enzyme responsible for the production of triglycerides in the liver. This leads to a reduction in the amount of triglycerides in the blood, which can help to reduce the risk of cardiovascular events.
Approved indications
- Hypertriglyceridemia
Common side effects
- Nausea
Key clinical trials
- Bioactive Smart Dressings for Diabetic Foot Ulcers: Randomized Controlled Trial (PHASE2)
- A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRIGEL CI brief — competitive landscape report
- TRIGEL updates RSS · CI watch RSS
- LobSor Pharmaceuticals AB portfolio CI